TABLE 1.
Patient characteristics of the total population
| Trait | Total sample | Men | Women |
|---|---|---|---|
| n | 446 | 221 (49.6%) | 225 (50.4%) |
| Age (y) | |||
| Mean ± SD | 41.5 ± 13.4 | 37.8 ± 11.9 | 45.2 ± 13.9 |
| Median | 40 | 36 | 44 |
| Daily dose in CPZeq | |||
| Median | 425 | 500 | 372 |
| Duration of disease (y) | |||
| Mean ± SD | 15.4 ± 11.5 | 13.1 ± 10.0 | 17.6 ± 12.5 |
| Median | 13 | 11 | 15 |
| Type of therapy | |||
| Conventional antipsychotics | 191 (42.8%) | 91 (41.2%) | 100 (44.4%) |
| Atypical antipsychotics | 176 (39.5%) | 78 (35.3%) | 98 (43.6%) |
| Combination therapy | 79 (17.7%) | 52 (23.5%) | 27 (12.0%) |
| Smoking (+/−/?) | 259 (58.1%) /179 (40.1%) /8 (1.8%) | 173 (78.3%) /46 (20.8%) /2 (0.9%) | 86 (38.2%) /133 (59.1%) /6 (2.7%) |
| Hyperprolactinaemia (+/−) | 227 (50.9%) /219 (49.1%) | 98 (44.3%) /123 (55.7%) | 129 (56.9%) /96 (42.7%) |
| Prolactin (ng/mL) total | |||
| Mean ± SD | 34.7 ± 29.5 | 25.7 ± 22.5 | 43.5 ± 32.8 |
| Range | 1.5–140.6 | 1.5–122.1 | 2.1–140.6 |
| Prolactin (ng/mL; HPRL+) | |||
| Mean ± SD | 55.9 ± 27.5 | 43.5 ± 23.2 | 65.3 ± 26.9 |
| Range | 20.2–140.6 | 20.2–122.1 | 25.1–140.6 |
| Prolactin (ng/mL; HPLR–) | |||
| Mean ± SD | 12.6 ± 5.8 | 11.5 ± 5.0 | 14.1 ± 6.4 |
| Range | 1.5–24.9 | 1.5–20.0 | 2.1–24.9 |
CPZeq, chlorpromazine equivalents; HPRL, hyperprolactinaemia.